Technology ID
TAB-4645
Borrelia hermsii Isolate for Diagnostic Development
E-Numbers
E-087-2017-0
Lead Inventor
Schriefer, Martin
Lead IC
CDC
ICs
CDC
Applications
Research Materials
Diagnostics
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
This technology includes Borrelia hermsii isolate for diagnostic development of serologic tests. Borrelia hermsii is the major identified cause of Tick-Borne Relapsing Fever (TBRF) in humans in the western United States. Initial signs and symptoms of infection include fever, nausea, headache and malaise. Most cases are diagnosed on clinical suspicion and epidemiologic risk. Common source, case clusters notable. Microscopy and serologic detection of antibody responses to infection may aid in the laboratory confirmation or infection. Culture recovery of the infectious agent is not often attempted.
Commercial Applications
Development of assays to aid in laboratory support of TBRF clinical diagnosis.
Competitive Advantages
Develop serologic tests for detection of antibody responses to infection.
Licensing Contact: